GUTS · Fractyl Health, Inc.
$0.39
-0.06 (-13.31%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$77.30M
Shares
159.18M
Volume · Oct 2
3.03M
Avg daily vol (3M)
1.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.45
Open$0.50
Day$0.43–0.51
52W close$0.39–2.37
Avg vol 30d1.9M
Short int2.7M · 1.7% float · 1.5d
Short vol60%
Last earningsJul 15, 2026
DataFeb 2024–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held May 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$93,000
Trailing 12 months
Net income (TTM)
−$105.65M
Trailing 12 months
Revenue growth YoY
-57.1%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$47.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+223.5%
Year over year · more shares
Price change (1Y)
-69.4%
Trailing year
Short interest
1.7%
Latest settlement · 1.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−48%
below
Price vs 50-day avg
−31%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−36%
trailing
6-month return
−2%
trailing
YTD return
−80%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +12 funds added
Insider flow
Accumulating
Net +$39.9K over 90 days · 0% sells
Short interest
Rising
1.69% of float · ▲ +21.5% MoM · 1.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
77 holders — mid 2-yr range
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−15%
Y/Y
Free cash flow
$-90.9M
Quant / Vol
risk profile
Volatility
114%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
13.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−48%
Bearish
Price vs 50-day avg
−31%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +12 funds added
Insider flow
Accumulating
Net +$39.9K over 90 days · 0% sells
Short interest
Rising
1.69% of float · ▲ +21.5% MoM · 1.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
77 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 3%
Range high $2
vs 200-day avg -48%
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -16.33M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GUTS
this stock
Fractyl Health, Inc.
|
$77.30M | -79.5% | -100.0% | — | 1.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GUTS | -4.2% | -36.3% | -2.2% | -17.3% | -79.5% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -3.8% | -36.2% | -14.6% | -17.5% | -91.6% |